Paradigm Biocapital Advisors LP — 13F Holdings & Portfolio

CIK 1855655 · latest 13F-HR filed 2026-08-14

Paradigm Biocapital Advisors LP manages $5.34B in 13F-reported U.S. long-equity assets across 28 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (22.31%), NUVL (13.70%), EWTX (7.77%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions, exited 14, added to 11, and trimmed 6.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
520 FIFTH AVENUE, 23RD FLOOR
NEW YORK, NY 10036
Phone
(646) 970-2123
Filing Manager
Paradigm Biocapital Advisors LP
NEW YORK, NY
Signatory
David Kim
Chief Operating Officer and Chief Compliance Officer
Loading holdings…
AUM

$5.34B

Long-equity book

Holdings

28

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+7 / −14 / ↑11 / ↓6

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • REVOLUTION MEDICINES INC$544.1M +84.1%
  • SPYRE THERAPEUTICS INC$242.3M +245.4%
  • NUVALENT INC$186.2M +34.1%
  • EDGEWISE THERAPEUTICS INC$183.1M +78.9%
  • GENMAB A/S$147.0M +68.8%
Show all 11 →

Top Trims

  • VAXCYTE INC-$154.8M -55.6%
  • INSMED INC-$63.8M -31.1%
  • TYRA BIOSCIENCES INC-$20.3M -25.8%
  • LEXEO THERAPEUTICS INC-$16.1M -45.2%
  • OLEMA PHARMACEUTICALS INC-$11.1M -9.3%
Show all 6 →

New Positions

  • ALNYLAM PHARMACEUTICALS INC$144.5M
  • MBX BIOSCIENCES INC$138.4M
  • JADE BIOSCIENCES INC$63.5M
  • ACHIEVE LIFE SCIENCE INC$32.3M
  • MAPLIGHT THERAPEUTICS INC$24.6M
Show all 7 →

Exited Positions

  • ARCELLX INC$663.0M
  • CENTESSA PHARMACEUTICALS PLC$142.0M
  • TERNS PHARMACEUTICALS INC$116.9M
  • CYTOKINETICS INC$97.6M
  • ABIVAX SA$86.0M
Show all 14 →
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 REVOLUTION MEDICINES INC RVMD 76155X100 $1.19B 22.31% 6,361,323 SH
2 NUVALENT INC NUVL 670703107 $731.7M 13.70% 5,924,433 SH
3 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $415.1M 7.77% 10,215,455 SH
4 GENMAB A/S GMAB 372303206 $360.8M 6.76% 13,133,131 SH
5 SPYRE THERAPEUTICS INC SYRE 00773J202 $341.0M 6.38% 3,840,778 SH
6 APOGEE THERAPEUTICS INC APGE 03770N101 $209.2M 3.92% 1,576,385 SH
7 ORUKA THERAPEUTICS INC ORKA 687604108 $204.1M 3.82% 2,144,526 SH
8 TANGO THERAPEUTICS INC TNGX 87583X109 $198.7M 3.72% 6,357,523 SH
9 BELITE BIO INC BLTE 07782B104 $189.8M 3.55% 1,232,877 SH
10 ERASCA INC ERAS 29479A108 $175.0M 3.28% 9,550,000 SH
11 TARSUS PHARMACEUTICALS INC TARS 87650L103 $174.7M 3.27% 2,775,649 SH
12 ALNYLAM PHARMACEUTICALS INC ALNY 02043Q107 $144.5M 2.71% 480,000 SH
13 INSMED INC INSM 457669307 $141.4M 2.65% 1,325,977 SH
14 MBX BIOSCIENCES INC MBX 55287L101 $138.4M 2.59% 2,508,015 SH
15 VAXCYTE INC PCVX 92243G108 $123.7M 2.32% 2,127,852 SH
16 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $123.5M 2.31% 6,723,788 SH
17 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $108.5M 2.03% 8,670,576 SH
18 JADE BIOSCIENCES INC JBIO 008064206 $63.5M 1.19% 2,857,405 SH
19 TYRA BIOSCIENCES INC TYRA 90240B106 $58.4M 1.09% 1,828,607 SH
20 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $42.7M 0.80% 1,553,748 SH
21 EYEPOINT INC EYPT 30233G209 $41.3M 0.77% 2,890,397 SH
22 ACHIEVE LIFE SCIENCE INC ACHV 004468500 $32.3M 0.61% 4,951,856 SH
23 VOR BIOPHARMA INC VOR 929033207 $32.2M 0.60% 1,750,000 SH
24 MAPLIGHT THERAPEUTICS INC MPLT 56565P103 $24.6M 0.46% 685,852 SH
25 KARDIGAN INC KARD 485925101 $21.5M 0.40% 900,000 SH
26 LEXEO THERAPEUTICS INC LXEO 52886X107 $19.4M 0.36% 4,175,382 SH
27 EDITAS MEDICINE INC EDIT 28106W103 $18.1M 0.34% 5,586,625 SH
28 INVENTIVA SA IVA 46124U107 $15.1M 0.28% 4,000,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $5.34B 28 0001855655-26-000014
2026-03-31 2026-05-15 $4.89B 35 0001855655-26-000011
2025-12-31 2026-02-17 $3.92B 30 0001855655-26-000003
2025-09-30 2025-11-14 $3.52B 36 0001855655-25-000014